CA3108697A1 - A pharmaceutical composition for safe and effective treatment of knee and/or hip pain - Google Patents
A pharmaceutical composition for safe and effective treatment of knee and/or hip pain Download PDFInfo
- Publication number
- CA3108697A1 CA3108697A1 CA3108697A CA3108697A CA3108697A1 CA 3108697 A1 CA3108697 A1 CA 3108697A1 CA 3108697 A CA3108697 A CA 3108697A CA 3108697 A CA3108697 A CA 3108697A CA 3108697 A1 CA3108697 A1 CA 3108697A1
- Authority
- CA
- Canada
- Prior art keywords
- pain
- pharmaceutical composition
- ngf
- antibody
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717435P | 2018-08-10 | 2018-08-10 | |
| US62/717,435 | 2018-08-10 | ||
| US201862764816P | 2018-08-15 | 2018-08-15 | |
| US62/764,816 | 2018-08-15 | ||
| PCT/US2019/045970 WO2020033872A1 (en) | 2018-08-10 | 2019-08-09 | A pharmaceutical composition for safe and effective treatment of knee and/or hip pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3108697A1 true CA3108697A1 (en) | 2020-02-13 |
Family
ID=67811008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3108697A Pending CA3108697A1 (en) | 2018-08-10 | 2019-08-09 | A pharmaceutical composition for safe and effective treatment of knee and/or hip pain |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11472870B2 (enExample) |
| EP (1) | EP3833687A1 (enExample) |
| JP (1) | JP7460598B2 (enExample) |
| KR (1) | KR20210043624A (enExample) |
| CN (1) | CN112839956A (enExample) |
| AU (1) | AU2019318556B2 (enExample) |
| CA (1) | CA3108697A1 (enExample) |
| IL (1) | IL280550B2 (enExample) |
| MX (1) | MX2021001549A (enExample) |
| WO (1) | WO2020033872A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7532290B2 (ja) * | 2021-03-09 | 2024-08-13 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム |
| WO2023092052A1 (en) | 2021-11-19 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| US20240002491A1 (en) * | 2022-04-27 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US8309088B2 (en) * | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| PL2187964T3 (pl) * | 2007-08-10 | 2015-03-31 | Regeneron Pharma | Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu |
| KR20130031247A (ko) * | 2010-03-17 | 2013-03-28 | 애보트 리서치 비.브이. | 항―신경 성장 인자（ｎｇｆ） 항체 조성물 |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| US9617334B2 (en) * | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| MA45890B2 (fr) | 2016-11-29 | 2022-10-31 | Regeneron Pharma | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes |
-
2019
- 2019-08-09 KR KR1020217007170A patent/KR20210043624A/ko not_active Ceased
- 2019-08-09 IL IL280550A patent/IL280550B2/en unknown
- 2019-08-09 CN CN201980066402.2A patent/CN112839956A/zh active Pending
- 2019-08-09 MX MX2021001549A patent/MX2021001549A/es unknown
- 2019-08-09 AU AU2019318556A patent/AU2019318556B2/en active Active
- 2019-08-09 US US16/536,706 patent/US11472870B2/en active Active
- 2019-08-09 WO PCT/US2019/045970 patent/WO2020033872A1/en not_active Ceased
- 2019-08-09 JP JP2021505954A patent/JP7460598B2/ja active Active
- 2019-08-09 CA CA3108697A patent/CA3108697A1/en active Pending
- 2019-08-09 EP EP19762255.8A patent/EP3833687A1/en active Pending
-
2021
- 2021-10-26 US US17/510,798 patent/US20220041708A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021533142A (ja) | 2021-12-02 |
| MX2021001549A (es) | 2021-04-13 |
| IL280550A (en) | 2021-03-25 |
| CN112839956A (zh) | 2021-05-25 |
| AU2019318556A1 (en) | 2021-03-04 |
| US11472870B2 (en) | 2022-10-18 |
| US20220041708A1 (en) | 2022-02-10 |
| JP7460598B2 (ja) | 2024-04-02 |
| US20200048337A1 (en) | 2020-02-13 |
| WO2020033872A1 (en) | 2020-02-13 |
| IL280550B1 (en) | 2025-02-01 |
| AU2019318556B2 (en) | 2026-05-14 |
| KR20210043624A (ko) | 2021-04-21 |
| IL280550B2 (en) | 2025-06-01 |
| EP3833687A1 (en) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7744190B2 (ja) | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 | |
| AU2021201118A1 (en) | Methods for reducing cardiovascular risk | |
| US20220041708A1 (en) | Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain | |
| TW202239767A (zh) | 用於治療類風濕性關節炎之組成物及方法 | |
| CA3235380A1 (en) | Methods for treating prurigo nodularis by administering an il-4r antagonist | |
| US11491222B2 (en) | Method of treating lower back pain | |
| KR20210122810A (ko) | 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체 | |
| US20220356261A1 (en) | Treatment for sjögren's syndrome | |
| US20250011408A1 (en) | Methods and compositions for reducing centralized pain | |
| RU2786232C2 (ru) | Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава | |
| US20240002491A1 (en) | Methods for selecting patients for treatment with an ngf antagonist | |
| EA044062B1 (ru) | Фармацевтическая композиция для предотвращения опиоидной зависимости | |
| CN117203232A (zh) | 用抗il-13抗体治疗特应性皮炎的方法 | |
| HK40011843A (en) | A pharmaceutical composition for averting opioid addiction | |
| EA041556B1 (ru) | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241104 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241119 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250410 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250804 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250804 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260709 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260723 |